Replies to post #247444 on Biotech Values

[vinmantoo]

Biotech investors (including analysts, CEOs, and myself in the past) confuse clinical utility with investability. My argument is that there is very little barrier to entry into the ADC space--identifying differentially expressed targets and attaching a cytotoxic molecule to them is relatively trivial. My argument is are they are not investable *moving forward*.

Seems like we disagree on just about everything. It is pretty astonishing to me that you dismiss the investment potential of ADCs as well as anti-cancer drugs. A barrier to entry is quite different from efficacy, safety and timing. ADC that are already shown to be effective as single agents will become the backbone of broader indications as combination drugs, especially with immuno-modulators. There are a lot of entrants into the T cell modulation field because the market is so broad, and successful therapies have longer duration of treatment.

You have told us a lot of what you don't like but not what you do like, going as far as to complain about what is discussed on this aboard. How about enlightening us on the what you do like?

[GrthzGd]

FWIW, SGEN has one of my companies' mAbs in an ADC clinical program at the moment. Hopefully, the target of the program proves vulnerable to its mAb (and, hopefully, the program itself survives the PFE closing).